Cempra Inc (CEMP) 19.00 $CEMP
Cempra (CEMP) Is Today's Strong On High Volume Stock
at The Street - Fri Dec 12, 9:13AM CST
Trade-Ideas LLC identified Cempra (CEMP) as a strong on high relative volume candidate
CEMP: 19.00 (+0.47)
Will Cempra (CEMP) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:20AM CST
Will Cempra (CEMP) Continue to Surge Higher?
CEMP: 19.00 (+0.47)
Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H2, 2014
M2 - Thu Dec 11, 6:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/24xkp9/communityacquired) has announced the addition of the "Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H2, 2014" report to their offering. Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H2, 2014" provides data on the Community-Acquired Bacterial Pneumonia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Community-Acquired Bacterial Pneumonia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Community-Acquired Bacterial Pneumonia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Actavis plc - Cempra, Inc. - Pfizer Inc. - Cempra Pharmaceuticals, Inc. - AstraZeneca PLC - Nabriva Therapeutics AG - Cubist Pharmaceuticals, Inc. - Boehringer Ingelheim Auslandsbeteiligungs GmbH - Bayer AG - Basilea Pharmaceutica AG Clinical Trial Overview of Top Institutes / Government - Yokohama Rosai Hospital - Nagasaki Evaluation Organization for Clinical Interventions - Central Japan Lung Study Group - Albany Medical Center For more information visit http://www.researchandmarkets.com/research/24...tyacquired
CBSTZ: 0.04 (-0.01), PFE: 30.95 (-0.70), AZN: 71.80 (-1.80), CEMP: 19.00 (+0.47)
Nasdaq stocks posting largest percentage increases
AP - Tue Dec 09, 5:10PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
OFED: 20.00 (+0.94), EFOI: 5.70 (+0.21), CBST: 96.31 (+0.04), AKAO: 11.91 (-0.31), CEMP: 19.00 (+0.47), PDCE: 33.13 (-0.89), MTEX: 28.10 (-1.00), OTIC: 36.72 (+2.60)
Analysts say two biotech firms may be targets after Merck-Cubist deal
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 12:20PM CST
AKAO: 11.91 (-0.31), CEMP: 19.00 (+0.47)
Cempra (CEMP) in Focus: Stock Rises 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 7:37AM CST
Cempra, Inc. (CEMP) was a big mover last session, as the company saw its shares rise more than 11% on the day.
LCI: 43.58 (-0.46), CEMP: 19.00 (+0.47), IG: 8.78 (+0.12), BIOD: 1.38 (-0.03)
Can Cempra (CEMP) Keep the Earnings Streak Alive This Quarter? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 7:52AM CST
Cempra has been witnessing a nice streak of beating earnings estimates. In fact, the company currently has a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming beat
CEMP: 19.00 (+0.47)
Cempra to Participate in Upcoming Investor Events in December
GlobeNewswire - Wed Dec 03, 3:10PM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in two upcoming investor events in December. Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will provide a company overview and update on its clinical development programs.
CEMP: 19.00 (+0.47)
Cempra Poised To Join Antibacterial Drug Acquisition Buzz With Upcoming Data Release
StockMatusow - at Seeking Alpha - Tue Nov 25, 7:00AM CST
TTPH: 31.57 (-0.39), CBST: 96.31 (+0.04), ROG: 68.50 (-0.90), CEMP: 19.00 (+0.47)
Cempra to Receive BARDA Funding for 1b and Start-Up of Phase 2/3 Solithromycin Pediatric Studies
GlobeNewswire - Wed Nov 19, 5:00AM CST
$16.0 Million Will be Provided to Cover the Cost of the Study and Other Activities Specified in the Contract
CEMP: 19.00 (+0.47)
Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak
Life Sciences Report - Seeking Alpha - Thu Nov 13, 3:24PM CST
What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corps? You get Steve Brozak, who brings his one-of-a kind perspective on the intricacies of Ebola virus disease to this interview...
TTPH: 31.57 (-0.39), JNJ: 104.43 (-2.29), BCRX: 10.06 (+0.02), NAVB: 1.49 (+0.19), CMRX: 35.45 (+0.83), SRPT: 13.97 (-0.33), NBS: 3.58 (+0.31), TKMR: 14.28 (+0.19), GSK: 42.42 (-0.93), CEMP: 19.00 (+0.47), OMER: 22.81 (+0.12)
Sucampo (SCMP) Worth Watching: Stock Moves 7.4% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 8:25AM CST
Sucampo Pharmaceuticals (SCMP) was a big mover last session, with shares rising over 7% on the day.
LCI: 43.58 (-0.46), SHPG: 213.70 (-0.41), SCMP: 13.93 (-0.13), CEMP: 19.00 (+0.47)
Cempra to Present at Two Upcoming Investor Conferences
GlobeNewswire - Mon Nov 10, 3:11PM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in two upcoming investor conferences. Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will provide a company overview and update on its clinical development programs.
CEMP: 19.00 (+0.47)
Moving Average Crossover Alert: Cempra (CEMP) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:10AM CST
Moving Average Crossover Alert: Cempra (CEMP)
CEMP: 19.00 (+0.47)
Why Cempra (CEMP) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 7:31AM CST
Cempra has decent short-term momentum and it is seeing solid activity on the earnings estimate revision front as well
CEMP: 19.00 (+0.47)
Strength Seen in Cempra (CEMP): Stock Rises 10.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:25AM CDT
Cempra (CEMP) was a big mover last session, with shares rising over 10% on the day.
LCI: 43.58 (-0.46), ADHD: 3.41 (+0.16), CEMP: 19.00 (+0.47), IG: 8.78 (+0.12)
More on Cempra Holdings Q3 results
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 4:47AM CDT
CEMP: 19.00 (+0.47)
Cempra tops Street 3Q forecasts
Automated Insights - Thu Oct 30, 4:03AM CDT
CHAPEL HILL, N.C. (AP) _ Cempra Inc. (CEMP) on Thursday reported a third-quarter loss of $11.4 million.
CEMP: 19.00 (+0.47)
Cempra (CEMP) Is Today's Strong On High Volume Stock
at The Street - Fri Dec 12, 9:13AM CST
Trade-Ideas LLC identified Cempra (CEMP) as a strong on high relative volume candidate
CEMP: 19.00 (+0.47)
Will Cempra (CEMP) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:20AM CST
Will Cempra (CEMP) Continue to Surge Higher?
CEMP: 19.00 (+0.47)
Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H2, 2014
M2 - Thu Dec 11, 6:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/24xkp9/communityacquired) has announced the addition of the "Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H2, 2014" report to their offering. Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H2, 2014" provides data on the Community-Acquired Bacterial Pneumonia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Community-Acquired Bacterial Pneumonia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Community-Acquired Bacterial Pneumonia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Actavis plc - Cempra, Inc. - Pfizer Inc. - Cempra Pharmaceuticals, Inc. - AstraZeneca PLC - Nabriva Therapeutics AG - Cubist Pharmaceuticals, Inc. - Boehringer Ingelheim Auslandsbeteiligungs GmbH - Bayer AG - Basilea Pharmaceutica AG Clinical Trial Overview of Top Institutes / Government - Yokohama Rosai Hospital - Nagasaki Evaluation Organization for Clinical Interventions - Central Japan Lung Study Group - Albany Medical Center For more information visit http://www.researchandmarkets.com/research/24...tyacquired
CBSTZ: 0.04 (-0.01), PFE: 30.95 (-0.70), AZN: 71.80 (-1.80), CEMP: 19.00 (+0.47)
Nasdaq stocks posting largest percentage increases
AP - Tue Dec 09, 5:10PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
OFED: 20.00 (+0.94), EFOI: 5.70 (+0.21), CBST: 96.31 (+0.04), AKAO: 11.91 (-0.31), CEMP: 19.00 (+0.47), PDCE: 33.13 (-0.89), MTEX: 28.10 (-1.00), OTIC: 36.72 (+2.60)
Analysts say two biotech firms may be targets after Merck-Cubist deal
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 12:20PM CST
AKAO: 11.91 (-0.31), CEMP: 19.00 (+0.47)
Cempra (CEMP) in Focus: Stock Rises 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 7:37AM CST
Cempra, Inc. (CEMP) was a big mover last session, as the company saw its shares rise more than 11% on the day.
LCI: 43.58 (-0.46), CEMP: 19.00 (+0.47), IG: 8.78 (+0.12), BIOD: 1.38 (-0.03)
Can Cempra (CEMP) Keep the Earnings Streak Alive This Quarter? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 7:52AM CST
Cempra has been witnessing a nice streak of beating earnings estimates. In fact, the company currently has a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming beat
CEMP: 19.00 (+0.47)
Cempra to Participate in Upcoming Investor Events in December
GlobeNewswire - Wed Dec 03, 3:10PM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in two upcoming investor events in December. Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will provide a company overview and update on its clinical development programs.
CEMP: 19.00 (+0.47)
Cempra Poised To Join Antibacterial Drug Acquisition Buzz With Upcoming Data Release
StockMatusow - at Seeking Alpha - Tue Nov 25, 7:00AM CST
TTPH: 31.57 (-0.39), CBST: 96.31 (+0.04), ROG: 68.50 (-0.90), CEMP: 19.00 (+0.47)
Cempra to Receive BARDA Funding for 1b and Start-Up of Phase 2/3 Solithromycin Pediatric Studies
GlobeNewswire - Wed Nov 19, 5:00AM CST
$16.0 Million Will be Provided to Cover the Cost of the Study and Other Activities Specified in the Contract
CEMP: 19.00 (+0.47)
Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak
Life Sciences Report - Seeking Alpha - Thu Nov 13, 3:24PM CST
What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corps? You get Steve Brozak, who brings his one-of-a kind perspective on the intricacies of Ebola virus disease to this interview...
TTPH: 31.57 (-0.39), JNJ: 104.43 (-2.29), BCRX: 10.06 (+0.02), NAVB: 1.49 (+0.19), CMRX: 35.45 (+0.83), SRPT: 13.97 (-0.33), NBS: 3.58 (+0.31), TKMR: 14.28 (+0.19), GSK: 42.42 (-0.93), CEMP: 19.00 (+0.47), OMER: 22.81 (+0.12)
Sucampo (SCMP) Worth Watching: Stock Moves 7.4% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 8:25AM CST
Sucampo Pharmaceuticals (SCMP) was a big mover last session, with shares rising over 7% on the day.
LCI: 43.58 (-0.46), SHPG: 213.70 (-0.41), SCMP: 13.93 (-0.13), CEMP: 19.00 (+0.47)
Cempra to Present at Two Upcoming Investor Conferences
GlobeNewswire - Mon Nov 10, 3:11PM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in two upcoming investor conferences. Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will provide a company overview and update on its clinical development programs.
CEMP: 19.00 (+0.47)
Moving Average Crossover Alert: Cempra (CEMP) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:10AM CST
Moving Average Crossover Alert: Cempra (CEMP)
CEMP: 19.00 (+0.47)
Why Cempra (CEMP) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 7:31AM CST
Cempra has decent short-term momentum and it is seeing solid activity on the earnings estimate revision front as well
CEMP: 19.00 (+0.47)
Strength Seen in Cempra (CEMP): Stock Rises 10.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:25AM CDT
Cempra (CEMP) was a big mover last session, with shares rising over 10% on the day.
LCI: 43.58 (-0.46), ADHD: 3.41 (+0.16), CEMP: 19.00 (+0.47), IG: 8.78 (+0.12)
More on Cempra Holdings Q3 results
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 4:47AM CDT
CEMP: 19.00 (+0.47)
Cempra tops Street 3Q forecasts
Automated Insights - Thu Oct 30, 4:03AM CDT
CHAPEL HILL, N.C. (AP) _ Cempra Inc. (CEMP) on Thursday reported a third-quarter loss of $11.4 million.
CEMP: 19.00 (+0.47)
